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http://dx.doi.org/10.1016/j.ccr.2014.04.017SUMMARYUveal melanoma (UM) is the most common cancer in adult eyes. Approximately 80% of UMs harbor somatic
activating mutations inGNAQ orGNA11 (encoding Gq or G11, respectively). Herein, we show in both cell cul-
ture and human tumors that cancer-associated Gq/11 mutants activate YAP, a major effector of the Hippo
tumor suppressor pathway that is also regulated by G protein-coupled receptor signaling. YAP mediates
the oncogenic activity of mutant Gq/11 in UM development, and the YAP inhibitor verteporfin blocks tumor
growth of UM cells containing Gq/11 mutations. This study reveals an essential role of the Hippo-YAP
pathway in Gq/11-induced tumorigenesis and suggests YAP as a potential drug target for UM patients car-
rying mutations in GNAQ or GNA11.INTRODUCTION
Uveal melanoma (UM) is the most common intraocular tumor in
adults and accounts for 5% of all melanomas (Singh et al.,
2005). UM frequently metastasizes to the liver along a hematog-
enous route, as 90% of UMmetastasis is found in the liver. Once
metastasized, there is no effective therapy, with average survival
of 2 to 8 months (Singh et al., 2005). Unlike cutaneous mela-
noma, UM originates from melanocytes of the choroid, ciliarySignificance
UM is the most common type of adult eye cancer. Currently th
Most UMs have activatingmutations in one of two homologous
tively). We found that the Hippo pathway effector YAP is activa
either genetic or pharmacological approaches blocks tumor gr
ing a strategy for UM intervention by inhibiting YAP. This me
signaling in tumorigenesis, may serve as a paradigm for gener
or mutations of G protein-coupled receptor or G proteins.
822 Cancer Cell 25, 822–830, June 16, 2014 ª2014 Elsevier Inc.body, and iris (collectively known as the uvea) derived from the
neural crest (Arnesen, 1985).
Molecular genetic analyses have shown that the mutational
spectrum of UM is very different from that of cutaneous mela-
noma. Instead of the BRAF or NRAS mutations common in
cutaneous melanoma, more than 80% of UMs carry activating
mutations in either GNAQ or GNA11 (Lamba et al., 2009; Van
Raamsdonk et al., 2009, 2010). Only UM derived from the iris,
a minor fraction (5%) of total UM cases, harborsBRAFmutationsere is no effective treatment, especially for metastatic UM.
Gproteins, Gq orG11 (encoded byGNAQ orGNA11, respec-
ted in UM containing mutant Gq/11, and inhibition of YAP by
owth of Gq/11-mutated UM cells in mouse models, suggest-
chanism, whereby YAP activation mediates mutant Gq/11
al pathogenesis of human cancers with aberrant expression
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Roles of the Hippo-YAP Pathway in Uveal Melanoma(Henriquez et al., 2007). Notably, the GNAQmutation is frequent
in benign blue nevi, whereas the GNA11 mutation is frequent in
malignant UM (Van Raamsdonk et al., 2010). The Gq and G11
proteins, encoded by the GNAQ and GNA11 genes, respec-
tively, are the alpha subunits of heterotrimeric G proteins that
play an obligatory role in G protein-coupled receptor (GPCR)
signaling. Interestingly, all mutations in Gq or G11 occur at either
arginine 183 (R183) or glutamine 209 (Q209) in a mutually exclu-
sive manner, suggesting that these mutations in Gq and G11
have similar functions in tumor promotion (Van Raamsdonk
et al., 2010). R183 and Q209 are located in the switch I and
switch II domains of Gq/11 proteins, respectively, and these mu-
tations convert the G proteins into a constitutively active form by
decreasing their guanosine triphosphatase activity. Therefore,
the cancer-associated mutant Gq/11 would induce constitutive
downstream signaling that presumably contributes to tumor
development.
Previous work has shown that overexpression of active Gq/11
can induce transformation of normal melanocytes (Van Raams-
donk et al., 2009, 2010). Moreover, downregulation of mutant
Gq/11 in UM cells abolished their ability to form tumors in immu-
nocompromised mice, demonstrating a direct cancer-driving
function of the active Gq/11 in tumorigenesis (Van Raamsdonk
et al., 2009, 2010). Although it has been proposed that Gq/11
activates the MAP kinase, the precise molecular mechanism of
these activating Gq/11 mutations in UM development remains
to be defined.
The Hippo tumor suppressor pathway normally functions
to control tissue homeostasis and limit organ size (Halder and
Johnson, 2011; Pan, 2010; Tapon and Harvey, 2012; Yu and
Guan, 2013). Core components of the Hippo pathway are repre-
sented by a kinase cascade consisting of MST1/2 and Lats1/2.
The Lats1/2 kinases phosphorylate and inactivate YAP and
TAZ, two homologous transcription coactivators with oncogenic
potential. In fact, elevated expression or nuclear enrichment of
YAP/TAZ has been observed in multiple types of human cancers
(Chan et al., 2008; Steinhardt et al., 2008; Zhao et al., 2007). We
recently reported that the Hippo pathway is strongly regulated by
GPCR signaling (Miller et al., 2012; Mo et al., 2012; Yu et al.,
2012). GPCR signaling can either activate or inhibit YAP activity
in a manner dependent on the coupled G protein. For example,
activation of G12/13 stimulates YAP by inducing YAP dephos-
phorylation, nuclear localization, and transcriptional activity,
whereas activation of Gs inhibits YAP by increasing YAP phos-
phorylation. Interestingly, expression of active Gq/11 (containing
the Q209L mutation), but not the wild-type, is able to stimulate
YAP/TAZ dephosphorylation (Yu et al., 2012), indicating that
YAP can be activated by Gq/11. These observations prompted
us to investigate if the Hippo-YAP pathway might function as a
mediator in active Gq/11-induced tumorigenesis, particularly in
UM development.
RESULTS
Activation of YAP by Mutant Gq/11 in UM
To test whether YAP can be activated by the cancer-associated
mutant Gq/11, we first determined the effects of GNAQ and
GNA11 hot spot mutations found in UM on YAP activity. In hu-
man embryonic kidney 293A (HEK293A) cells, ectopic expres-sion of mutant Gq/11 (GqR183Q, GqQ209L, or G11Q209L), but not
the wild-type Gq or G11, caused a dramatic dephosphorylation
of cotransfected YAP, as indicated by faster migration of YAP
on a phos-tag-containing gel (Figure 1A). Because phosphoryla-
tion inhibits YAP, these data suggest that mutant Gq/11 acti-
vates YAP. TAZ has two phosphodegrons and Lats-induced
phosphorylation promotes TAZ ubiquitination and degradation
(Huang et al., 2012; Liu et al., 2010). As expected, the endoge-
nous TAZ protein levels were significantly increased in the pres-
ence of mutant Gq/11 (Figure 1A). Lats-induced phosphorylation
inhibits YAP/TAZ by promoting YAP/TAZ cytoplasmic seques-
tration, while dephosphorylated YAP/TAZ translocate to the
nucleus and stimulate gene expression. Consistently, overex-
pression of active Gq/11 mutants, but not wild-type Gq/11,
induced nuclear localization of endogenous YAP/TAZ, as as-
sessed by immunofluorescence staining with an antibody that
recognizes both YAP and TAZ (Figures S1A–S1C available on-
line). These results show that the mutant Gq/11 found in UM
potently activates YAP/TAZ and suggest a model that activation
of YAP/TAZmay contribute to mutant Gq/11-induced UM devel-
opment, given the known oncogenic function of these two tran-
scription coactivators.
We then investigated YAP/TAZ activation status in a panel
of 13 cell lines established from primary or metastatic UM
by different laboratories. We sequenced the genes of GNAQ
and GNA11. Among these UM cell lines, seven (92.1, Mel202,
Mel270, OMM1.3, OMM2.2, OMM2.3, and OMM2.5) contain
the GqQ209 mutation, one (OMM1) contains the G11Q209L muta-
tion, and the remaining five tumor lines (OCM1, OCM3, OCM8,
Mel285, and Mel290) have no mutations in Gq/11 (Figure 1B).
These data are consistent with other recently reported mutation
analyses, and among these cell lines, three (OCM1, OCM3, and
OCM8) contain BRAFV600E mutations (Griewank et al., 2012).
Next, we determined YAP/TAZ phosphorylation and subcellular
localization for each of these UM cell lines. Interestingly, all UM
cell lines with Gq/11 mutations displayed low or moderate YAP
phosphorylation and strong nuclear YAP (or YAP/TAZ) local-
ization (Figure 1B). On the other hand, YAP was highly phos-
phorylated and exhibited exclusive cytoplasmic localization in
BRAF-mutant cells (Figure 1B). These observations demonstrate
that YAP is activated in Gq/11-mutant UM cells but inactivated in
BRAF-mutant cells.
YAP/TAZ are known to be activated by serum or lysophospha-
tidic acid (LPA) (Miller et al., 2012; Yu et al., 2012). Both serum
and LPA activate YAP/TAZ by inducing rapid dephosphorylation
and nuclear localization. In UM cells with wild-type Gq/11 and
BRAF, serum and LPA induced a strong YAP dephosphorylation
and concomitantly increased YAP nuclear localization (Figures
1B–1D; Figures S1D and S1E). In contrast, in UM cells containing
mutated Gq/11, YAP was dephosphorylated and localized in the
nucleus regardless of the serum or LPA conditions. Our findings
show that YAP/TAZ are indeed more active in UM cell lines con-
taining Gq/11 mutations and are no longer sensitive to serum or
LPA. Notably, in UM cells with mutant BRAF, YAP was heavily
phosphorylated, and the serum and LPA-induced YAP dephos-
phorylation and nuclear localization were blunted (Figures
1B–1D; Figures S1D and S1E). In support, Lats phosphorylation
status, an indicator of kinase activity, was higher in BRAF-mutant
cells than in Gq/11-mutant cells (Figure S1F). These dataCancer Cell 25, 822–830, June 16, 2014 ª2014 Elsevier Inc. 823
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Figure 1. Activation of YAP by Mutant Gq/11 in UM Cell Lines
(A) Effects of UM-associated mutant Gq/11 on YAP/TAZ activity. HEK293A cells were transfected with different Gq/11 plasmids together with FLAG-YAP, and
following 12 hr serum starvation, cells were harvested and YAP/TAZ activation status was analyzed by immunoblotting using the indicated antibodies. YAP
phosphorylation was assessed using gels containing phos-tag, which slows down migration of phosphorylated YAP during electrophoresis. Endogenous TAZ
protein levels were determined with a TAZ-specific antibody. For the Gq plasmids, two concentrations of plasmids were used in transfection, and the expression
levels of transfected Gq were determined by immunoblotting.
(B) Table summarizing Gq/11 or BRAF mutation status, YAP phosphorylation, YAP localization, and responses to serum of multiple UM cells. Cyto, cytoplasm;
Nuc, nucleus; WT, wild-type. The number of plus signs indicates the strength. *Information from Griewank et al. (2012).
(C) YAP phosphorylation and response to serum in representative UM cell lines. UM cells were cultured with or without 10% FBS for 16 hr.
(D) YAP localization and response to serum in representative UM cell lines. Cells were maintained in the presence or absence of 10% FBS for 16 hr, and
after fixation, YAP localization was determined by immunostaining. The green and blue colors represent YAP and DNA staining, respectively. The scale bars
represent 5 mm.
See also Figure S1.
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BRAF-mutant cells, and moreover, active BRAF might suppress
YAP activation.
Previously, Gq/11 mutant-induced activation of the extracel-
lular-signal-regulated kinases (ERKs), also known as MAP ki-
nase, was proposed as a potential mechanism for mutant Gq/
11 in UM development (Van Raamsdonk et al., 2009, 2010).
Indeed, overexpression of Gq/11 mutants moderately induces
phosphorylation of ERK (Van Raamsdonk et al., 2009, 2010).
On the basis of western blot analyses of the 13 UM cell lines,
ERK phosphorylation in Gq/11-mutant UMcell lines was evident,
however it was much lower than that of BRAF-mutant UM cells
(Figure 1B; Figure S1D). Moreover, ERK phosphorylation in the
Gq/11-mutant UM cells was no higher than that in UM cells
(Mel285 and Mel290) without Gq/11 mutations, suggesting that
the ERK pathway is unlikely a major mediator for UM driven by
mutant Gq/11. On the basis of the above data, we speculate
that YAP/TAZ activation may play an important role in UM
tumorigenesis.824 Cancer Cell 25, 822–830, June 16, 2014 ª2014 Elsevier Inc.Activation of YAP in UMs with Gq/11 Mutations
To determine YAP/TAZ activation status in UM, we exam-
ined formalin-fixed, paraffin-embedded sections of enucle-
ated tumors. We collected 23 UM samples and performed
genomic DNA sequencing for exon 4 (R183) and exon 5
(Q209) of Gq/11. Thirteen UM samples had Q209 mutations,
whereas none had R183 mutation in Gq/11 (Table S1).
The same clinical samples were immunostained using a
YAP or YAP/TAZ antibody (Figure 2A; Table S1). The subcel-
lular localization of YAP was assessed and scored from 1
to 5, with 1 representing exclusive nuclear localization and 5
representing exclusive cytoplasmic localization (Table S1).
When YAP localization data were compared with the mutation
status of Gq/11, we observed a strong correlation between
mutated Gq/11 and YAP nuclear localization (Figure 2B). On
the basis of these observations, we conclude that mutated
Gq/11 is associated with YAP activation in UM, supporting a
possible pathological role of YAP in Gq/11 mutation-induced
tumorigenesis.
A B
Figure 2. YAP Nuclear Localization Correlates with Gq/11 Mutations in UM Specimens
(A) Representative images for YAP localization in UM specimens. Immunofluorescence staining was performed for YAP (green) and DNA (blue, 40,6-diamidino-2-
phenylindole). Shown are three representative samples of wild-type (left) and Gq/11 mutant (right). The scale bars represent 10 mm.
(B) Correlation between YAP nuclear localization and Gq/11 mutation in UM specimens. The subcellular localization of YAP were scored from 1 to 5, with 1
representing exclusive nuclear localization and 5 representing for exclusive cytoplasmic localization. Student’s t test (two tailed, 95% confidence intervals) was
used for statistical analysis, and error bars represent SD.
See also Table S1.
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In a subcutaneous xenograft mouse model, 92.1 (GqQ209L) cells
transfected with small hairpin RNA (shRNA) targeting Gq failed to
develop tumor (Figure 3A), confirming an essential role for mutant
Gq in tumorigenicity of 92.1 cells. We tested whether the mutant
Gq is required for high YAP activity in UM cells. In both 92.1 and
Mel270 (GqQ209P) cells, we established stable lines expressing
control shRNA or Gq shRNAs (#1 and #2 target different regions).
Knockdown of Gq was confirmed by western blotting (Figure 3B).
Weobserved that YAP phosphorylation (as indicated by the phos-
phorylatedYAPwesternblot)was increased incells expressingGq
shRNA (Figure 3B). When dephosphorylated, YAP localizes in the
nucleus and interacts with the TEAD family of transcription factors
to stimulate gene transcription (Cao et al., 2008; Wu et al., 2008;
Zhang et al., 2008; Zhao et al., 2008).We examined the interaction
of YAP with TEAD. In Gq-knockdown cells, the interaction of YAP
and TEADwas decreased, whereas Gq knockdown had no effect
on TEAD1 expression (Figure 3C). In addition, YAP nuclear locali-
zationwas decreased inGq-knockdowncells (Figures 3D and 3E),
consistent with YAP inactivation. We have recently shown that
Gs-protein kinase A (PKA) signaling stimulates YAP/TAZ phos-
phorylation, an effect opposite to Gq/11 activation (Kim et al.,
2013; Yuet al., 2013;Yuet al., 2012). Asexpected, YAPphosphor-
ylation was increased in 92.1 cells when treated with forskolin and
3-isobutyl-1-methylxanthine (IBMX), which increase cellular cyclic
AMP and activate PKA (Figure 3F). Notably, forskolin and IBMX
induced stronger YAP phosphorylation in the Gq-knockdown
92.1 cells (Figure 3F), indicating that the active mutant Gq in 92.1
cells functions antagonistically to PKA. The above data support a
function for mutant Gq in maintaining YAP in a dephosphorylated
and activated status in UM cells.
YAP Is Required forMutant Gq/11, but NotMutant BRAF,
Driving Tumorigenesis
Expression of active Gq/11 (Q209L) in immortalizedmelanocytes
(melan-a cells) is sufficient to induce cell transformation (VanRaamsdonk et al., 2009, 2010). This offers a well-defined and
cleaner system for functional studies than UM-derived cell lines,
which certainly contain mutations besides Gq/11. In melan-a
cells expressing GqQ209L or G11Q209L, YAP phosphorylation
was reduced (Figures S2A and S2B), and the YAP-TEAD inter-
action was increased (Figure S2C), indicating higher YAP
activity. To test the role of YAP/TAZ in GqQ209L-induced cell
transformation, we generated GqQ209L-stable melan-a cells
expressing control, YAP, and/or TAZ shRNAs (Figure 4A). As
an indicator of transformation, GqQ209L-stable melan-a cells,
but not control melan-a cells expressing GFP, could support
anchorage-independent growth in soft agar. Importantly,
GqQ209L-stable melan-a cells expressing YAP and/or TAZ
shRNAs failed to form colonies (Figures 4B; Figure S2D). In addi-
tion, when subcutaneously grafted into nude mice, GqQ209L-sta-
ble melan-a cells with YAP knockdown exhibited a significant
reduction in tumor growth (Figures 4C; Figure S2H). These re-
sults indicate that YAP/TAZ are important for Gq-induced
neoplastic transformation.
To investigate the role of YAP in the tumorigenesis of UM-
derived cell lines, we attempted to knock down YAP in 92.1 cells
(GqQ209L), which have high YAP activity, and OCM1 (BRAFV600E)
cells, which have low YAP activity. Although it was easy to knock
down YAP in OCM1 cells, we failed to establish an efficient YAP
knockdown in 92.1 cells (data not shown). These observations
suggest a critical role for YAP in 92.1 cell proliferation, which
may be addicted to high YAP activity.We thenmade an inducible
shRNA (pTRIPz system) containing the same YAP targeting
sequences used in the conventional vector (pLKO.1) and suc-
cessfully established both 92.1 and OCM1 stable cells. YAP
expression in these cell lines was effectively reduced upon doxy-
cycline (Dox) treatment that induced expression of the shRNAs
(Figure 4D). In vitro, the proliferation of 92.1 cells was slightly
reduced upon Dox treatment, whereas knockdown of YAP
in OCM1 cells showed no significant effect on cell proliferation
(Figures S2E and S2F). We also assessed the cell-migratoryCancer Cell 25, 822–830, June 16, 2014 ª2014 Elsevier Inc. 825
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Figure 3. Downregulation of Mutant Gq in
UM Cells Inactivates YAP
(A) Tumor formation ability of 92.1 (GqQ209L) cells
with or without Gq knockdown. Control or Gq-
knockdown 92.1 cells were grafted into nude mice
subcutaneously, and tumor formation was moni-
tored. Knockdown efficiency is shown in (B). Error
bars represent SD.
(B) Effect of Gq knockdown on YAP phos-
phorylation. Stable 92.1 cells expressing con-
trol shRNA (shCTL) or two Gq-targeting
shRNAs (shGq#1 and shGq#2) were estab-
lished. Gq knockdown efficiency and YAP
phosphorylation in these cells were assessed
by western blotting. pYAP indicates western
blotting with an antibody that specially recog-
nizes the S127 phosphorylated YAP. The same
experiment was performed in Mel270 (GqQ209P)
cells.
(C) Effect of Gq knockdown on YAP-TEAD
interaction. Immunoprecipitation (IP) of YAP from
control or Gq-knockdown cell lysates was per-
formed, and TEAD1 coprecipitated was deter-
mined by immunoblotting.
(D and E) Effect of Gq knockdown on YAP sub-
cellular localization. Control or Gq-knockdown
92.1 cells were serum starved for 16 hr and fixed, and YAP localization was determined. The scale bars represent 5 mm.
(F) Effect of Gq knockdown on PKA-induced YAP phosphorylation (inactivation). Control or Gq-knockdown cells were treated with forskolin (10 mM) and
IBMX (100 mM) for 1 hr, and then YAP phosphorylation was determined. Both forskolin and IBMX increase cAMP and activate PKA, which stimulates YAP
phosphorylation.
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Roles of the Hippo-YAP Pathway in Uveal Melanomapotential of these cells. Again, knockdown of YAP in 92.1 but
not OCM1 cells reduced cell migration in a transwell assay (Fig-
ures 4E; Figure S2G). Furthermore, knockdown of YAP greatly
impaired tumor formation of 92.1 cells (Figure 4F) but not
OCM1 (Figure 4G) or OCM8 (Figure 4H) cells in nude mice (Fig-
ure S2H). Together, these observations suggest that YAP plays
a pivotal role in tumorigenesis of Gq/11Q209L-induced, but not
BRAFV600E-induced, UM.
The YAP-Inhibitory Drug Verteporfin Selectively
Suppresses Gq/11-Mutant UM Tumorigenesis
The strongcorrelationbetween theGq/11mutation andYAPacti-
vation inUMspecimensandUMcell linesand theeffectivenessof
YAP knockdown in preventing tumor growth of Gq/11-mutated
UM cells in a mouse xenograft model prompted us to test the ef-
fect of pharmacological inhibition of YAP on the tumorigenesis of
UM cells. It has recently been reported that the porphyrin-family
compounds, such as verteporfin, disrupt the YAP-TEAD interac-
tion and therefore inhibit the function of YAP in liver size control
(Liu-Chittenden et al., 2012). Verteporfin is a drug with Food
and Drug Administration (FDA) approval for photodynamic ther-
apy to eliminate abnormal blood vessels in the eye (Bressler
and Bressler, 2000). Interestingly, when treated with verteporfin,
the UM cells with Gq/11 mutations were effectively killed, as
indicated by the cleavage of poly (ADP-ribose) polymerase-1
(PARP1, an apoptosis marker; Figure 5A; Figure S3A). Similarly,
the Gq/11-mutant UM cells were sensitive to growth inhibition
by verteporfin (Figure S3B). In comparison, the BRAF-mutant
cells weremore resistant to both growth inhibition and apoptosis
in response to verteporfin treatment (Figure 5A; Figures S3A and
S3B). On the other hand, the BRAF-mutant UM cells were more826 Cancer Cell 25, 822–830, June 16, 2014 ª2014 Elsevier Inc.easily killed by U0126 (an inhibitor for MAP kinase kinase
[MEK], the ERK-activating kinase), while the Gq-mutant cells
were resistant to U0126 (Figure 5B). These results suggest a
model in which YAP activation is more important for Gq/11-
mutant tumor cells, whereas ERK activation is more important
for BRAF-mutant tumor cells. Our data indicate that verteporfin
may be used to selectively kill tumor cells with elevated YAP
activity, such as UM containing mutations in Gq/11.
To assess the role of verteporfin in inhibiting tumorigenesis of
UM cells, we used an orthotopic mousemodel. Tumor cells were
injected into the suprachoroidal space of the eye of the severe
combined immunodeficient (SCID) mice. Tumor formation was
monitored by noninvasive fundus examinations and optical
coherent tomography (OCT) in live animals and histological
analyses after mice were euthanized (Figures S3C and S3D).
Aggressive endophytic growth was seen in 92.1 cells, resulting
in filling of the inside of the eye with tumor cells (Figures S3C
and S3D). We investigated the effect of verteporfin on the inhibi-
tion of tumor growth in vivo. Clinical-grade verteporfin (40 mg/in-
jection) was packaged into nanoparticles and mixed with 92.1,
Mel270, or OCM1 cells prior to injection into the eye. As negative
controls, UM cells were coinjected with empty nanoparticles.
For the verteporfin-treated group, mice were also administered
100 mg/kg verteporfin along an intraperitoneal route every other
day over a period of 14 days, whereas control mice were injected
with PBS. After 6 weeks, compared with the control group, ver-
teporfin treatment significantly reduced tumor growth of the Gq
mutant 92.1 and Mel270 cells (Figures 5C and 5D; Figures S3E
and S3F). In contrast, verteporfin treatment had little effect on
tumor growth of the BRAF-mutant OCM1 cells (Figures 5E and
5F). Therefore, these mouse model studies demonstrate that
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Figure 4. YAP Is Required for Mutant Gq/11-Induced Tumorigenesis
(A) Knockdown of YAP and/or TAZ in melan-a cells expressing GqQ209L.
(B) Effect of YAP and/or TAZ knockdown on anchorage-independent growth of melan-a cells expressingGqQ209L. Different melan-a cell lines were cultured in soft
agar, and colony formation was assessed. GFP and GqQ209L denote melan-a cells stably expressing GFP control and GqQ209L, respectively. shRNA knockdown
of YAP and/or TAZ is indicated; Y/T stands for combination of YAP and TAZ shRNAs.
(C) Tumorigenicity of the GqQ209L expressing melan-a cells following YAP knockdown. The same cell lines used in (B) were grafted into nude mice subcuta-
neously, and tumor formation was monitored.
(D) Inducible knockdown of YAP in 92.1 or OCM1 cells. Cells were treated with Dox (2.5 mg/ml) for 3 days, and YAP knockdown was assessed by immunoblotting.
(E) The effect of YAP knockdown on cell migration. Migration potential of 92.1 or OCM1 cells following YAP knockdown was assessed using a transwell assay.
(F–H) Tumorigenicity of Gq (92.1) mutant and BRAF (OCM1 and OCM8) mutant UM cells following YAP knockdown. Control or YAP knockdown 92.1 (F), OCM1
(G), or OCM8 (H) cells were grafted into nude mice subcutaneously, and tumor formation was monitored. Student’s t test (two tailed, 95% confidence intervals)
was used for statistical analysis, and error bars represent SD.
See also Figure S2.
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Roles of the Hippo-YAP Pathway in Uveal Melanomaverteporfin is effective in inhibiting tumor cell growth and might
be considered for targeted treatment of UM with Gq/11 muta-
tions and elevated YAP activity.
DISCUSSION
UM is the most common intraocular tumor in adults and
frequently metastasizes to the liver. Early-stage UM can be
treated by radiation or enucleation (removal of the eye), but there
is no effective treatment for metastatic UM, which is the most
feared complication and the main cause of death (Singh et al.,
2005). Enucleation has been the last resort to prevent metastasis
and has a long-lasting adverse and psychological impact on pa-
tients, even though enucleation does not significantly improve
the outcome of survival (Collaborative Ocular Melanoma Study
Group, 1998). Therefore, a systemic treatment of metastasis is
urgently needed. The high penetrance of Gq/11-activating muta-
tions and the essential role of mutant Gq/11 in UM oncogenesis
warrants the need for an in-depth mechanistic understanding of
Gq/11 in tumorigenesis. Moreover, the establishment of mutant
Gq/11 as a cancer driver suggests a potential of developing tar-geted therapies for UM treatment. Unfortunately, a drug that tar-
gets constitutively active Gq/11 is currently not available. It is
therefore important to identify downstream effectors essential
for Gq/11-induced tumorigenesis, and these effectors may pro-
vide opportunities to develop molecular-targeted drugs for UM
management.
In this report, we reveal a strong correlation between Gq/11
mutations and YAP activation in UM. We have established a
causal relationship between Gq/11mutation and YAP activation,
and we show that YAP is essential in transducing the oncogenic
activity of mutant Gq/11 to induce UM. Thus, YAPmay serve as a
drug target for pharmaceutical intervention of UM. Indeed, this
concept is strongly supported by our data showing that down-
regulation of YAP selectively inhibits tumor growth of UM cells
containing mutated Gq/11. Furthermore, verteporfin inhibits
the proliferation of UM cells with Gq/11 mutations in vitro and
is effective in suppressing their growth in a mouse model. Verte-
porfin is already an FDA-approved drug for eye disease indica-
tions such as macular degeneration, so it would be relatively
easy to adapt this drug for UM treatment. Hence, the result of
UM inhibition by verteporfin offers exciting possibilities notCancer Cell 25, 822–830, June 16, 2014 ª2014 Elsevier Inc. 827
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Figure 5. YAP Inhibitor Suppresses Tumor Growth of Gq/11-Mutated UM Cells
(A) Sensitivity of Gq/11-mutant and BRAF-mutant UM cells to verteporfin, a YAP inhibitor. Gq-mutant cells or BRAF-mutant cells were treated with 0.2 or 1 mg/ml
of verteporfin for 48 hr, and cell lysates were assessed for PARP1 cleavage (the black arrow indicates the position of cleaved PARP1, an indicator of cell death).
(B) Sensitivity of Gq/11-mutant and BRAF-mutant UM cells to U0126, a MEK inhibitor. UM cells were treated with 5 and 25 mM of U0126 for 36 hr, and then cell
apoptosis was assessed by PARP1 cleavage.
(C and D) Effects of verteporfin treatment on tumor growth of 92.1 cells in an orthotopic UM mouse model. Before injection into the suprachoroidal space of the
eye, 92.1 cells were mixed with nanoparticles containing verteporfin or buffer (control [CTL]). After injection, verteporfin was delivered systematically to mice
(treated) via intraperitoneal injection. Tumor formationwasmonitored byOCT, and tumors were harvested and sectioned for histological analysis. Representative
sections of the eye showed the presence of large pigmented melanoma xenografts filling the eyes of all vehicle-treated animals (C, left), whereas tumors in the
verteporfin treatment group (C, right) were smaller, as indicated by black arrows. The tumor areas from five injected eyes were quantified and are shown in (D).
(E and F) Effect of verteporfin treatment on tumor growth of OCM1 cells. Similar experiments were performed as in (C) and (D) using OCM1 cells. Student’s t test
(two tailed, 95% confidence intervals) was used for statistical analysis, and error bars represent SD. The scale bars represent 100 mm.
See also Figure S3.
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metastasis. Notably, the FDA-approved application of vertepor-
fin is based on photodynamic therapy to eliminate neovasculari-
zation of blood vessels. Light activation of the drug is required
for verteporfin to inhibit neovascular angiogenesis but is not
required to disrupt the interaction between YAP and TEAD
(Liu-Chittenden et al., 2012). Therefore, verteporfin could have
a dual function, inhibiting angiogenesis and YAP activity, both
of which can positively contribute to inhibiting UM. Our data indi-
cate that verteporfin should be considered for UM treatment. It is
equally important to note that verteporfin is ineffective toward
the BRAF-mutant UM cells, which are sensitive to MEK inhibi-
tors. These observations suggest that the therapeutic effects
of verteporfin observed on the Gq/11 mutant UM cells are not
due to general toxicity but rather target specific and mecha-
nism-based inhibition of the Gq/11-mutant UM cells.
It has been previously shown that the active Gq/11mutant also
stimulates the ERK pathway (Van Raamsdonk et al., 2009, 2010).
This is not surprising, because G proteins are known to initiate
multiple downstream signaling events. However, activation of
the ERK pathway by active Gq/11 is less potent compared
with that of the BRAFV600E mutation, which is frequently found
in cutaneous melanoma (Figure 1B; Figure S1D). BRAF inhibition
is an effective target-based therapy commonly used to treat
BRAFV600E mutant melanoma. Our study indicates that YAP acti-828 Cancer Cell 25, 822–830, June 16, 2014 ª2014 Elsevier Inc.vation is more important than ERK activation in UM. Consistent
with this notion, downregulation of YAP or verteporfin treatment
induces more cell death and tumor inhibition in Gq/11-mutant
UM cells than in BRAF-mutant UM cells (Figures 4F–4H and 5).
Further studies are needed to determine the effect of a combined
treatment inhibiting both MEK and YAP in treating UM with the
Gq/11 mutation.
YAP/TAZ are frequently activated in human cancers (Harvey
et al., 2013). However, the underlying mechanisms leading to
YAP/TAZ activation in cancers are largely unknown. Mutations
in the Hippo pathway components are rare in human cancers.
One notable example is the neurofibromin 2 (NF2) tumor sup-
pressor. Mutation in NF2 activates YAP, and YAP activation is
required for NF2-induced tumorigenesis (Zhang et al., 2010).
Our report not only reveals a mechanism of YAP activation in
Gq/11-induced tumorigenesis but also suggests that YAP acti-
vation plays a critical role in cancer development with altered
GPCR signaling. In addition to UM, other types of neoplastic
lesions, such as blue nevi (Van Raamsdonk et al., 2009) and
leptomeningeal melanocytic lesions (Ku¨sters-Vandevelde et al.,
2010) also contain prevalent Gq/11 mutations. More recently,
the GqR183Q mutation has been identified in 80% to 90% of
Sturge-Weber syndrome and port-wine stain patients (Shirley
et al., 2013). We also showed that GqR183Q also potently acti-
vated YAP (Figure 1A; Figures S1A–S1C). Interestingly, most of
Cancer Cell
Roles of the Hippo-YAP Pathway in Uveal Melanomathese tumors or overgrowths, including those caused by NF2
loss-of-function mutations, are derived from the neuroectoderm.
Activation of YAP/TAZ by Gq/11 or NF2 mutations in these tu-
mors suggests that the Hippo pathway plays an important role
in the development and differentiation of the neuroectoderm,
consistent with a role of the Hippo pathway in regulating neural
progenitor cells (Cao et al., 2008).
GPCRs constitute the largest family of cell surface receptors
encoded by the human genome. Although cancer-associated
mutations in GPCR signaling are less frequent than receptor
tyrosine kinases, extensive cancer genome sequencing has re-
vealed that approximately 20% of all human cancers may have
altered GPCR signaling (O’Hayre et al., 2013). For example, mu-
tation of metabotropic glutamate receptor occurs at an appre-
ciable frequency in cutaneous melanoma (Prickett et al., 2011).
Besides genetic alterations (mutation or amplification), GPCRs
are stimulated by their cognate ligands, and therefore altered
ligand levels can also lead to abnormal GPCR signaling. For
example, LPA is a potent mitogen and strongly activates YAP/
TAZ (Miller et al., 2012; Yu et al., 2012). In fact, LPA is elevated
and defined as a biomarker for ovarian cancer (Mills and Moole-
naar, 2003). We have recently shown that YAP is broadly regu-
lated by a large number of GPCRs (Yu et al., 2012). Collectively,
these observations suggest a potential paradigm that YAP acti-
vation plays a broad role in cancers driven by altered GPCR
signaling, and thus YAP inhibitors, such as verteporfin, represent
a potential therapeutic for cancers with altered GPCR signaling.
EXPERIMENTAL PROCEDURES
More experimental procedures are shown in the Supplemental Information.
Cell Culture
UM cell lines, provided by Dr. Martine Jager (Leiden University), were main-
tained in RPMI 1640 medium with 10% fetal bovine serum (FBS). Melan-a
cells, a gift from Dr. Dorothy Bennett (St. George University), were cultured
in RPMI medium with 10% FBS and 200 nM 12-O-tetradecanoylphorbol-
13-acetate. HEK293A, human embryonic kidney 293T, and human embryonic
kidney 293P cells were cultured in Dulbecco’s modified Eagle’s medium with
10%FBS. All media were supplementedwith 50 mg/ml penicillin/streptomycin.
Cells were maintained at 37C with 5% CO2.
Animal Work
All animal procedures were carried out according to protocols approved by
the Institutional Animal Care and Use Committee of the University of California,
San Diego. For subcutaneous xenograft experiments, 12-week-old male nude
mice were used. Cells (melan-a, 92.1, OCM1, or OCM8) with manipulations of
YAP or Gq expression were grafted subcutaneously into both flanks of mice,
and tumor growth was monitored three times a week. Mice were euthanized
after 10 weeks of cell injection or until the tumor size reached 1 cm3 to docu-
ment the formation of primary tumors. For the orthotopic UM mouse model,
male 4-week-old SCID mice were used. Mice were anesthetized, and 50,000
cells of 92.1, Mel270, or OCM1 were injected into the suprachoroidal space
in the right eye using a 33-gauge needle. Tumor formation was monitored
every week by fundus examinations and OCT (Spectralis; Heiderberg Engi-
neering). Mice were euthanized after 6 weeks because of the development
of very large masses in the eyes of several mice in the control group. Eyes
were enucleated and fixed in 4%paraformaldehyde and subjected to histolog-
ical analysis.
Human Clinical Samples
Patients were diagnosed with UM by clinical history, complete ophthalmic ex-
amination, ultrasound, and ancillary studies. Twenty-three enucleated eyesdue to large UM lesions were collected with patients’ consent and approval
of the Institutional Review Board of West China Hospital. UM specimens
were paraffin embedded and sectioned for histology and immunofluorescence
staining. The use of human tissue samples was in accordance with the proto-
cols approved by the Institutional Review Boards at West China Hospital and
the University of California, San Diego.
Other methods are described in Supplemental Experimental Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.ccr.2014.04.017.
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